Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012:2012:816274.
doi: 10.1155/2012/816274. Epub 2012 Feb 8.

Neurogenic bladder

Affiliations

Neurogenic bladder

Peter T Dorsher et al. Adv Urol. 2012.

Abstract

Congenital anomalies such as meningomyelocele and diseases/damage of the central, peripheral, or autonomic nervous systems may produce neurogenic bladder dysfunction, which untreated can result in progressive renal damage, adverse physical effects including decubiti and urinary tract infections, and psychological and social sequelae related to urinary incontinence. A comprehensive bladder-retraining program that incorporates appropriate education, training, medication, and surgical interventions can mitigate the adverse consequences of neurogenic bladder dysfunction and improve both quantity and quality of life. The goals of bladder retraining for neurogenic bladder dysfunction are prevention of urinary incontinence, urinary tract infections, detrusor overdistension, and progressive upper urinary tract damage due to chronic, excessive detrusor pressures. Understanding the physiology and pathophysiology of micturition is essential to select appropriate pharmacologic and surgical interventions to achieve these goals. Future perspectives on potential pharmacological, surgical, and regenerative medicine options for treating neurogenic bladder dysfunction are also presented.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Anatomy and physiology of micturition with potential injury sites to urologic system (m: muscarinic receptor, α: alpha-adrenergic receptor, β: beta-adrenergic receptor).

References

    1. Wein AJ. Lower urinary tract dysfunction in neurologic injury and disease. In: Wein AJ, Kavoussi LR, Novick AC, Partin AW, Peters CA, editors. Campbell-Walsh Urology. 9th edition. New York, NY, USA: Saunders; 2007. pp. 2011–2045.
    1. Lansang RS, Krouskop AC. Bladder management. In: Massagli TL, et al., editors. eMedicine. 2004.
    1. Manack A, Motsko SP, Haag-Molkenteller C, et al. Epidemiology and healthcare utilization of neurogenic bladder patients in a US claims database. Neurourology and Urodynamics. 2011;30(3):395–401. - PubMed
    1. Verhoef M, Lurvink M, Barf HA, et al. High prevalence of incontinence among young adults with spina bifida: description, prediction and problem perception. Spinal Cord. 2005;43(6):331–340. - PubMed
    1. O'Leary M, Dierich M. Botulinum toxin type A for the treatment of urinary tract dysfunction in neurological disorders. Urologic Nursing. 2010;30(4):228–234. - PubMed

LinkOut - more resources